喻青松

男， 北京化工大學(xué)， 教授/研究員/教授級(jí)高工或同等級(jí)別

學(xué)習(xí)/工作經(jīng)歷

2004.9-2008.6，北京化工大學(xué)，生物功能材料，本科
2008.9-2014.6，中科院化學(xué)所，高分子化學(xué)與物理，博士
2014.7-2017.6，北京化工大學(xué)生命學(xué)院，博士后
2017.7-2023.12，北京化工大學(xué)生命學(xué)院，副教授
2024.1-至今，北京化工大學(xué)生命學(xué)院，教授

研究領(lǐng)域和興趣

高分子抗腫瘤納米制劑

主要業(yè)績(jī)

得益于其對(duì)原藥毒性的改善作用，高分子抗腫瘤納米制劑在腫瘤治療研究中備受關(guān)注，但療效不足仍是其目前應(yīng)用面臨的最大障礙。高分子抗腫瘤納米制劑通常由高分子載體通過(guò)化學(xué)或物理方式結(jié)合治療藥物構(gòu)成，載體的化學(xué)組成和結(jié)構(gòu)直接影響納米藥物的尺寸、穩(wěn)定性、表面性質(zhì)等表觀納米特性，進(jìn)而決定藥物的體內(nèi)命運(yùn)。因此，高分子納米制劑成功的關(guān)鍵在于深刻理解并合理運(yùn)用載體化學(xué)組成結(jié)構(gòu)與其體內(nèi)遞送過(guò)程的相關(guān)性。
近年來(lái)，為了解決納米藥物研究和臨床轉(zhuǎn)化過(guò)程中所面臨的諸多關(guān)鍵科學(xué)問(wèn)題，申請(qǐng)人以臨床研究常見(jiàn)的聚合物及其衍生物作為主要研究對(duì)象，圍繞高分子納米藥物面臨的級(jí)聯(lián)生理屏障特征開(kāi)展系列研究，試圖闡明高分子載體組成結(jié)構(gòu)及其所決定的納米特性與生理屏障之間的相關(guān)性，借此指導(dǎo)臨床可用高效抗腫瘤納米藥物的設(shè)計(jì)。取得代表性學(xué)術(shù)成果如下：
1. 揭示載體組成結(jié)構(gòu)與體內(nèi)遞送過(guò)程相關(guān)性，發(fā)展高效納米藥物設(shè)計(jì)策略，系統(tǒng)克服級(jí)聯(lián)生理屏障。
2. 發(fā)展腫瘤特異性激活納米前藥策略，實(shí)現(xiàn)安全高效的放化療增敏以及腫瘤局部治療。
3. 提出新型免疫聯(lián)合治療策略，推動(dòng)高效抗腫瘤納米藥物的臨床轉(zhuǎn)化。
申請(qǐng)人從癌癥治療這一關(guān)系國(guó)計(jì)民生的重大需求出發(fā)，積極探索通過(guò)關(guān)鍵技術(shù)的原始創(chuàng)新來(lái)解決目前納米藥物臨床應(yīng)用中所面臨的諸多關(guān)鍵科學(xué)問(wèn)題，主持包括國(guó)家自然科學(xué)基金優(yōu)青青年基金在內(nèi)的多項(xiàng)國(guó)家自然科學(xué)基金項(xiàng)目和企業(yè)橫向項(xiàng)目。在此基礎(chǔ)上獲得多項(xiàng)具有自主知識(shí)產(chǎn)權(quán)的新型載體材料和高端抗腫瘤納米制劑技術(shù)并著手相關(guān)技術(shù)的臨床轉(zhuǎn)化。申請(qǐng)人的研究工作密切聯(lián)系臨床實(shí)踐，不僅為多種類(lèi)型癌癥的臨床治療提供了潛在的解決方案，也有望改善相關(guān)癌癥的治療效果并增加新型納米藥物的患者可及性?；谏鲜鲅芯砍晒?，申請(qǐng)人在Adv. Mater.、Adv. Funct. Mater.等國(guó)內(nèi)外期刊發(fā)表學(xué)術(shù)論文40余篇，其中以第一/通訊作者發(fā)表SCI論文34篇，申請(qǐng)中國(guó)發(fā)明專利25項(xiàng)/PCT專利3項(xiàng)，授權(quán)中國(guó)發(fā)明專利13項(xiàng)/PCT專利3項(xiàng)，并多次受邀在全國(guó)高分子學(xué)術(shù)論文報(bào)告會(huì)、CASNN年會(huì)、中國(guó)生物醫(yī)學(xué)工程大會(huì)生物醫(yī)用材料臨床轉(zhuǎn)化分論壇、第五屆國(guó)際納米藥物大會(huì)等國(guó)內(nèi)/國(guó)際會(huì)議進(jìn)行學(xué)術(shù)報(bào)告。

代表成果

1. Kunpeng Liu, Binbin Jiao, Guan Zhang, Zhihua Gan, Shicong Lai,* Zhenshan Ding,* Qingsong Yu,* Self-enhanced ROS-responsive camptothecin prodrug nanoparticles elicit safe and efficient intravesical instillation therapy of bladder cancer. Journal of Controlled Release, 2025, 113905;
2. Shuchen Yu, Yitong Jiang, Qian Li, Mengmeng Li, Jiamin Su, Shicong Lai, Zhihua Gan, Zhenshan Ding*, Qingsong Yu,* Nano-sensitizer with self-amplified drug release and hypoxia normalization properties potentiates efficient chemoradiotherapy of pancreatic cancer. Biomaterials, 2024, 310, 122634;
3. Chunyu Yang, Yitong Jiang, Kaixin Zhang, Xianqi Zhu, Jianlin Li, Haiwang Yu, Jiawei Chen, Xinggui Gu,* Zhihua Gan, Qingsong Yu,* Photodynamic Therapy Derived Personalized Whole Cell Tumor Vaccine Prevents Postsurgery Tumor Recurrence and Metastasis. Small, 2024, 23084;
4. Jianlin Li, Haiwang Yu, Yan Kang, Kun Niu, Ming Wang, Yitong Jiang, Ni Jiang, Zhenshan Ding,* Zhihua Gan,* Qingsong Yu,* STING Membrane Prevents Post-Surgery Tissue Adhesion and Tumor Recurrence of Colorectal Cancer. Adv. Mater. 2024, 36, 2309655;
5. Chunyu Yang, Lixin Guo, Kaixin Zhang, Guan Wang, Qingsong Yu,* Zhihua Gan, Xinggui Gu,* Diradical-Featured Organic Small-Molecule Photothermal Material Based on 4,6-di(2-thienyl)thieno[3,4-c][1,2,5] thiadiazole for Photothermal Immunotherapy. Adv. Funct. Mater. 2023, 33, 2306360;
6. Xianqi Zhu, Lin Li, Jin Tang, Chunyu Yang, Hao Yu, Kunpeng Liu, Ziyan Zheng, Xinggui Gu *, Qingsong Yu *, Fu-Jian Xu, Zhihua Gan, Cascade-responsive nano-assembly for efficient photothermal-chemo synergistic inhibition of tumor metastasis by targeting cancer stem cells. Biomaterials, 2022, 280, 121305;
7. Lanqiong Zhang, Xiaomeng Du, Qian Li, Lili Qian, Jiawei Chen, Chaoyong Liu,* Qingsong Yu,* and Zhihua Gan, A Multimodal Therapeutic Nanoplatform Overcoming Tumor Hypoxia Heterogeneity for Improved Tumor Chemoradiotherapy. Adv. Funct. Mater. 2022, 2204629;
8. Xiaohu Tang, Xiaomeng Du, Yanting Yu, Meng Qin, Lili Qian, Meng Zhang, Yan Yang, Qingsong Yu,* and Zhihua Gan,* Deep-Penetrating Triple-Responsive Prodrug Nanosensitizer Actuates Efficient Chemoradiotherapy in Pancreatic Ductal Adenocarcinoma Models. Small 2022, 18, 2202834;
9. Yuqiang Li, Yitong Jiang, Ziyan Zheng, Nan Du, Shuli Guan, Wenxuan Guo, Xiaohu Tang, Jiajunzi Cui, Lanqiong Zhang, Kunpeng Liu, Qingsong Yu,* Zhihua Gan,* Co-Delivery of Precisely Prescribed Multi-Prodrug Combination by an Engineered Nanocarrier enables Efficient Individualized Cancer Chemotherapy. Adv. Mater. 2022, 2110490;
10. Yanting Yu, Keqi Xiang, Mingzhi Xu, Yuqiang Li, Jiajunzi Cui, Lanqiong Zhang, Xiaohu Tang, Xianqi Zhu, Lili Qian, Meng Zhang, Yan Yang, Qingsong Yu,* Youqing Shen, and Zhihua Gan, Prodrug Nanomedicine Inhibits Chemotherapy-Induced Proliferative Burst by Altering the Deleterious Intercellular Communication. ACS Nano 2021, 15, 781?796.

*以上信息由高級(jí)會(huì)員個(gè)人更新和維護(hù)。